Login to Your Account



Diabetes Cure?

VC-01 Diabetes Therapy 'Cells' Investors on Viacyte

By Marie Powers
Staff Writer

Thursday, July 11, 2013
Tiny Viacyte Inc. is going after a whopper of an indication with a stem cell-derived cell therapy to treat Type I and insulin-dependent Type II diabetes. The novelty of its combination product, known as VC-01 , lured its largest investors – Johnson & Johnson Development Corp., Sanderling Ventures and Asset Management Company (Johnson Trust) – back to the table for a private equity round.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription